Have a feature idea you'd love to see implemented?
Let us know!
ADAP Adaptimmune Therapeutics PLC
Price (delayed)
$0.6049
Market cap
$155.09M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.12
Enterprise value
$110.17M
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform
Highlights
Adaptimmune Therapeutics's gross profit has surged by 146% YoY and by 24% QoQ
The company's revenue has surged by 146% YoY and by 24% QoQ
The debt has surged by 191% year-on-year and by 57% since the previous quarter
Adaptimmune Therapeutics's equity has decreased by 17% from the previous quarter and by 9% YoY
Key stats
What are the main financial stats of ADAP
Market
Valuations
Earnings
Shares outstanding
256.39M
Market cap
$155.09M
Enterprise value
$110.17M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.94
Price to sales (P/S)
0.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.63
Revenue
$175.04M
Gross profit
$175.04M
Net income
-$44.52M
EBIT
-$41.65M
EBITDA
-$30.39M
Free cash flow
-$55.17M
Per share
Balance sheet
Liquidity
EPS
-$0.12
EPS diluted
-$0.18
Free cash flow per share
-$0.22
Book value per share
$0.31
Revenue per share
$0.68
TBVPS
$1.22
Total assets
$317.44M
Total liabilities
$237.45M
Debt
$74.5M
Equity
$79.99M
Working capital
$180.76M
Debt to equity
0.93
Current ratio
3.85
Quick ratio
3.17
Net debt/EBITDA
1.48
Margins
Efficiency
Dividend
EBITDA margin
-17.4%
Gross margin
100%
Net margin
-25.4%
Operating margin
-25.8%
Return on assets
-15.1%
Return on equity
-74.1%
Return on invested capital
-38.3%
Return on capital employed
-16.4%
Return on sales
-23.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADAP stock price
How has the Adaptimmune Therapeutics stock price performed over time
Intraday
0.82%
1 week
4.28%
1 month
-9%
1 year
37.07%
YTD
-23.72%
QTD
-36.35%
Financial performance
How have Adaptimmune Therapeutics's revenue and profit performed over time
Revenue
$175.04M
Gross profit
$175.04M
Operating income
-$45.1M
Net income
-$44.52M
Gross margin
100%
Net margin
-25.4%
Adaptimmune Therapeutics's gross profit has surged by 146% YoY and by 24% QoQ
The company's revenue has surged by 146% YoY and by 24% QoQ
ADAP's operating margin has soared by 84% YoY and by 53% QoQ
The net margin has surged by 81% year-on-year and by 50% since the previous quarter
Growth
What is Adaptimmune Therapeutics's growth rate over time
Valuation
What is Adaptimmune Therapeutics stock price valuation
P/E
N/A
P/B
1.94
P/S
0.89
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.63
Adaptimmune Therapeutics's EPS has soared by 75% YoY and by 50% from the previous quarter
ADAP's price to book (P/B) is 71% lower than its last 4 quarters average of 6.6 and 39% lower than its 5-year quarterly average of 3.2
Adaptimmune Therapeutics's equity has decreased by 17% from the previous quarter and by 9% YoY
The company's revenue has surged by 146% YoY and by 24% QoQ
The P/S is 99% below the 5-year quarterly average of 108.1 and 87% below the last 4 quarters average of 6.7
Efficiency
How efficient is Adaptimmune Therapeutics business performance
Adaptimmune Therapeutics's ROS has soared by 82% YoY and by 52% from the previous quarter
Adaptimmune Therapeutics's return on assets has surged by 50% YoY and by 40% QoQ
The company's return on invested capital rose by 48% QoQ and by 30% YoY
The return on equity is up by 37% since the previous quarter and by 26% year-on-year
Dividends
What is ADAP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADAP.
Financial health
How did Adaptimmune Therapeutics financials performed over time
ADAP's total assets is 34% greater than its total liabilities
The company's quick ratio rose by 44% YoY and by 18% QoQ
ADAP's current ratio is up by 32% YoY and by 25% QoQ
The debt is 7% smaller than the equity
The debt has surged by 191% year-on-year and by 57% since the previous quarter
ADAP's debt to equity has surged by 90% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.